Medtronic, Inc.'s New Endeavor(R) Zotarolimus-Eluting Stent Approved for Patients with Coronary Artery Disease in Canada
MISSISSAUGA, Canada & MINNEAPOLIS--(BUSINESS WIRE)--Medtronic of Canada Ltd. announced today that Medtronic, Inc. (NYSE:MDT), has received regulatory approval from Health Canada’s Therapeutic Products Directorate (TPD) for use of the Endeavor drug-eluting coronary stent (DES) system in the treatment of coronary artery disease. The company expects to begin commercial sales of the Endeavor stent in Canada by the end of March.